Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 395-401

  Buchler, T ^a   Klapka, R ^b   Melichar, B ^c   Brabec, P ^b   Dusek L ^b   Vyzula, R ^b,d   Abrahamova, J ^a  

^a FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

ALPHA INTERFERON; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER REGISTRY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CZECH REPUBLIC; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEPHRECTOMY; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SKIN TOXICITY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84856362744     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr065     Document Type: Article

References (23)

1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-3318.
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
4. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
5. Merseburger AS, Simon A, Waalkes S, Kuczyk MA. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2009; 9: 1429-1434.
6. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
7. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463.
8. Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008; 54: 1373-1378.
9. Choueiri TK, Brick AJ, McDermott S et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann Oncol 2008; 19 (Suppl 8): 593P.
10. Richter S, Pfister D, Thüer D et al. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 2008; 31 (Suppl 4): V684.
11. Sepulveda J, Maroto P, Andres R et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts. J Clin Oncol 2008; 26 (Suppl): (Abstr 16100).
12. Shepard DR, Rini BI, Garcia A et al. A multicenter prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008; 26 (Suppl): (Abstr 5123).
13. Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal carcinoma. J Urol 2009; 182: 29-34.
14. Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 81-86.
15. Porta C, Procopio G, Sabbatini R et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur Urol 2009; 8 (Suppl 4): 183 (Abstr 252).
16. Dudek AZ, Zolnierek J, Dham A et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-67.
17. Zimmermann K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009; 76: 350-354.
18. Melichar B. How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy? Oncology 2009; 77: 82-91.
19. Beck J, Procopio G, Bajetta E, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011; 22: 1812-1823.
20. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
21. Hutson TE, Bellmunt J, Porta C et al. Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): data analysis from patients (pts) treated for over 1 year in the phase III TARGET study. J Clin Oncol 2009; 27 (Suppl): (Abstr 16057).
22. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
23. Di Lorenzo G, Buonerba C, Federico P et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010;; 58: 906-911.